Folate status and birth defect risk: Epidemiological perspective

Folate in Health and Disease, Second Edition

Volumn , Issue , 2009, Pages 133-153

  Hobbs, Charlotte A ^a   Shaw, Gary M ^b   Werler, Martha M ^c   Mosley, Bridget ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79956320401     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Brender JD, Suarez L. Paternal occupation and anencephaly. Am J Epidemiol 1990; 131:517-21.
2. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod Toxicol 1991; 5:301-35.
3. Carmichael SL, Shaw GM. Maternal life event stress and congenital anomalies. Epidemiology 2000; 11:30-35.
4. Hobbs CA, Sherman SL, Yi P, Hopkins SE, Torfs CP, Hine RJ, Pogribna M, Rozen R, James SJ. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000; 67:623-30.
5. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol 2000; 151:878-84.
6. Hobbs CA, Cleves MA, Simmons CJ. Genetic epidemiology and congenital malformations: From the chromosome to the crib. Arch Pediatr Adolesc Med 2002; 156:315-20.
7. MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-37.
8. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341:1485-90.
9. Shaw GM, Lammer EJ, Wasserman CR, O’Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconcep-tionally. Lancet 1995; 346:393-96.
10. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285:2981-86.
11. Shaw GM, O’Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995; 59:536-45.
12. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999; 150:675-82.
13. Simmons CJ, Mosley BS, Fulton-Bond CA, Hobbs CA. Birth defects in Arkansas: Is folic acid fortification making a difference? Birth Defects Res A Clin Mol Teratol 2004; 70:559-64.
14. Canfield MA, Collins JS, Botto LD, Williams LJ, Mai CT, Kirby RS, Pearson K, Devine O, Mulinare J. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: Findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 2005; 73:679-89.
15. Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. Epidemiology1995; 6:212-18.
16. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ (Clin Res Ed) 1981; 282:1509-11.
17. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Walker S, Schorah CJ, Wild J. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1:1027-31.
18. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988; 260:3141-45.
19. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262:2847-52.
20. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-35.
21. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269:1257-61.
22. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995; 6:219-26.
23. Khoury MJ, Shaw GM, Moore CA, Lammer EJ, Mulinare J. Does periconceptional multivitamin use reduce the risk of neural tube defects associated with other birth defects? Data from two population-based case-control studies. Am J Med Genet 1996; 61:30-36.
24. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992; 41:1-7.
25. Take Folic Acid before You’re Pregnant. March of Dimes. http://www.marchofdimes.com/hbhb_syndication/18613_769.asp. Updated December 2008.
26. Nutrition during Pregnancy. American College of Obstetricians and Gynecologists Committee on Patient Education. http://www.acog.org/publications/patient_education/bp001.cfm. Updated June 2008.
27. Folic acid for the prevention of neural tube defects. American Academy of Pediatrics. Committee on Genetics. Pediatrics 1999; 104:325-27.
28. Institute of Medicine. Dietary Reference Intake: Folate, Other B Vitamins, and Choline. Washington, DC: National Academy Press, 1998.
29. Department of Health and Human Services, Food and Drug Administration. Food Standards: Amendment of Standards of Identity for Enriched Grain Products to Require Addition of Folic Acid. 21 CFR Parts 136,137,139, 8781-8797. 1996. 91N-100S.
30. Li Z, Ren A, Zhang L, Ye R, Li S, Zheng J, Hong S, Wang T, Li Z. Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res A Clin Mol Teratol 2006; 76:237-40.
31. Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard School of Public Health, 1996.
32. Shaw GM, Jensvold NG, Wasserman CR, Lammer EJ. Epidemiologic characteristics of phenotypically distinct neural tube defects among 0.7 million California births, 1983-1987. Teratology 1994; 49:143-49.
33. Hendricks KA, Simpson JS, Larsen RD. Neural tube defects along the Texas-Mexico border, 1993-1995. Am J Epidemiol 1999; 149:1119-27.
34. Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, Devine O, et al.National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006; 76:747-56.
35. Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics 2005; 116:580-86.
36. O’Rahilly R, Muller F. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology 2002; 65:162-70.
37. Khoury MJ, Erickson JD, James LM. Etiologic heterogeneity of neural tube defects: Clues from epidemiology. Am J Epidemiol 1982; 115:538-48.
38. Simpson JL, Mills J, Rhoads GG, Cunningham GC, Conley MR, Hoffman HJ. Genetic heterogeneity in neural tube defects. Ann Genet 1991; 34:279-86.
39. Rasmussen SA, Frias JL. Genetics of syndromic neural tube defects. In: Wyszynski DF, ed., Neural Tube Defects: From Origin to Treatment. New York: Oxford University Press, 2006:185-97.
40. Dunlevy LP, Chitty LS, Burren KA, Doudney K, Stojilkovic-Mikic T, Stanier P, Scott R, Copp AJ, Greene ND. Abnormal folate metabolism in foetuses affected by neural tube defects. Brain 2007; 130:1043-49.
41. Elwood JM, Little J, Elwood JH. Epidemiology and control of neural tube defects. In: Kelsey JL, Marmot MG, Stolley PD, Vessey MP, eds., Monographs in Epidemiology and Biostatistics. Oxford, UK: Oxford University Press, 1992.
42. Saul RA. Genetic counseling and interpretation of risk figures. In: Wyszynski DF, ed., Neural Tube Defects: From Origin to Treatment. New York: Oxford University Press, 2006:330-332.
43. Kalter H. Folic acid and human malformations: A summary and evaluation. Reprod Toxicol 2000; 14:463-76.
44. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev 2001; CD001056.
45. Green NS. Folic acid supplementation and prevention of birth defects. J Nutr 2002; 132:2356S-60S.
46. Laurence KM, James N, Miller M, Campbell H. Increased risk of recurrence of pregnancies complicated by fetal neural tube defects in mothers receiving poor diets, and possible benefit of dietary counselling. BMJ 1980; 281:1592-94.
47. Smithells RW, Sheppard S, Schorah CJ. Vitamin dificiencies and neural tube defects. Arch Dis Child 1976; 51:944-50.
48. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child 1981; 56:911-18.
49. Seller MJ, Nevin NC. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. J Med Genet 1984; 21:325-30.
50. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990; 10:149-52.
51. Holmes-Siedle M, Dennis J, Lindenbaum RH, Galliard A. Long term effects of peri-conceptional multivitamin supplements for prevention of neural tube defects: A seven to 10 year follow up. Arch Dis Child 1992; 67:1436-41.
52. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: Evidence from a case-control study in Western Australia. Med J Aust 1989; 150:613-19.
53. Moore LL, Bradlee ML, Singer MR, Rothman KJ, Milunsky A. Folate intake and the risk of neural tube defects: An estimation of dose-response. Epidemiology 2003; 14:200-05.
54. Suarez L, Hendricks KA, Cooper SP, Sweeney AM, Hardy RJ, Larsen RD. Neural tube defects among Mexican Americans living on the US-Mexico border: Effects of folic acid and dietary folate. Am J Epidemiol 2000; 152:1017-23.
55. Mills JL, Rhoads GG, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Walden ME, Depp OR, Hoffman HJ. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. National Institute of Child Health and Human Development Neural Tube Defects Study Group. N Engl J Med 1989; 321:430-35.
56. Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, Sever LE, Miller LA, Meaney FJ, Levitt M. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002; 66:33-39.
57. Pfeiffer CM, Johnson CL, Jain RB, Yetley EA, Picciano MF, Rader JI, Fisher KD, Mulinare J, Osterloh JD. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988-2004. Am J Clin Nutr 2007; 86:718-27.
58. Chen BH, Carmichael SL, Selvin S, Abrams B, Shaw GM. NTD prevalences in central California before and after folic acid fortification. Birth Defects Res A Clin Mol Teratol 2008; 82:547-52.
59. Folate status in women of childbearing age--United States, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:962-65.
60. Mosley BS, Cleves MA, Siega-Riz AM, Shaw GM, Canfield MA, Waller DK, Werler MM, Hobbs CA, National Birth Defects Prevention Study. Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the U.S. Am J Epidemiol 2009; 169:9-17.
61. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608-14.
62. Yates JR, Ferguson-Smith MA, Shenkin A, Guzman-Rodriguez R, White M, Clark BJ. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987; 31:279-87.
63. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995; 274:1698-702.
64. Ray JG, Meier C, Vermeulen MJ, Cole DE, Wyatt PR. Prevalence of trisomy 21 following folic acid food fortification. Am J Med Genet A 2003; 120A:309-13.
65. Venn BJ, Mann JI, Williams SM, Riddell LJ, Chisholm A, Harper MJ, Aitken W, Rossaak JI. Assessment of three levels of folic acid on serum folate and plasma homocysteine: A randomised placebo-controlled double-blind dietary intervention trial. Eur J Clin Nutr 2002; 56:748-54.
66. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Finkelstein JD, Blom HJ, Thomas CM, Borm GF, Wouters MG, Eskes TK. Maternal hyperhomocysteinemia: A risk factor for neural-tube defects? Metabolism 1994; 43:1475-80.
67. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet1995; 345:149-51.
68. van der Put NM, Blom HJ. Neural tube defects and a disturbed folate dependent homocysteine metabolism. Eur J Obstet Gynecol Reprod Biol 2000; 92:57-61.
69. van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: An overview. Exp Biol Med (Maywood) 2001; 226:243-70.
70. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: Effect of folic acid. Proc Natl Acad Sci USA 1996; 93:15227-32.
71. Chern CL, Huang RF, Chen YH, Cheng JT, Liu TZ. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother 2001; 55:434-42.
72. Finkelstein JD. The metabolism of homocysteine: Pathways and regulation. Eur J Pediatr 1998; 157(Suppl 2):S40-S44.
73. Zhao W, Mosley BS, Cleves MA, Melnyk S, James SJ, Hobbs CA. Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism. Birth Defects Res A Clin Mol Teratol 2006; 76:230-36.
74. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, Quadros EV. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350:134-42.
75. Shaw GM, Velie EM, Schaffer DM. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-affected pregnancies? Teratology 1997; 56:295-99.
76. Velie EM, Block G, Shaw GM, Samuels SJ, Schaffer DM, Kulldorff M. Maternal supplemental and dietary zinc intake and the occurrence of neural tube defects in California. Am J Epidemiol 1999; 150:605-16.
77. Shaw GM, Todoroff K, Schaffer DM, Selvin S. Periconceptional nutrient intake and risk for neural tube defect-affected pregnancies. Epidemiology 1999; 10:711-16.
78. Suarez L, Hendricks K, Felkner M, Gunter E. Maternal serum B12 levels and risk for neural tube defects in a Texas-Mexico border population. Ann Epidemiol 2003; 13:81-88.
79. Friel JK, Frecker M, Fraser FC. Nutritional patterns of mothers of children with neural tube defects in Newfoundland. Am J Med Genet 1995; 55:195-99.
80. Hendricks KA, Nuno OM, Suarez L, Larsen R. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 2001; 12:630-35.
81. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA 1996; 275:1093-96.
82. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275:1089-92.
83. Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz AM, Gallaway MS, Correa A. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 2007; 161:745-50.
84. World Health Organization. Typical Orofacial Clefts—Cumulative Data by Register. World Health Organization, 2007. Available at http://www.who.int/genomics/anoma-lies/cumulative_data/en/print.html; accessed June 26, 2008.
85. Badovinac RL, Werler MM, Williams PL, Kelsey KT, Hayes C. Folic acid-containing supplement consumption during pregnancy and risk for oral clefts: A meta-analysis.Birth Defects Res A Clin Mol Teratol 2007; 79:8-15.
86. Khoury MJ, Cordero JF, Mulinare J, Opitz JM. Selected midline defect associations: A population study. Pediatrics 1989; 84:266-72.
87. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. Teratology 2001; 63:79-86.
88. Conway H. Effect of supplemental vitamin therapy on the limitation of incidence of cleft lip and cleft palate in humans. Plast Reconstr Surg Transplant Bull 1958; 22:450-53.
89. Briggs RM. Vitamin supplementation as a possible factor in the incidence of cleft lip/palate deformities in humans. Clin Plast Surg 1976; 3:647-52.
90. Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982; 2:217.
91. Tolarova M. Orofacial clefts in Czechoslovakia. Incidence, genetics and prevention of cleft lip and palate over a 19-year period. Scand J Plast Reconstr Surg Hand Surg1987; 21:19-25.
92. Shaw GM, Carmichael SL, Laurent C, Rasmussen SA. Maternal nutrient intakes and risk of orofacial clefts. Epidemiology 2006; 17:285-91.
93. Wilcox AJ, Lie RT, Solvoll K, Taylor J, McConnaughey DR, Abyholm F, Vindenes H, Vollset SE, Drevon CA. Folic acid supplements and risk of facial clefts: National population based case-control study. BMJ 2007; 334:464.
94. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2:839-43.
95. Hill L, Murphy M, McDowall M, Paul AH. Maternal drug histories and congenital malformations: Limb reduction defects and oral clefts. J Epidemiol Community Health1988; 42:1-7.
96. Wong WY, Eskes TK, Kuijpers-Jagtman AM, Spauwen PH, Steegers EA, Thomas CM, Hamel BC, Blom HJ, Steegers-Theunissen RP. Nonsyndromic orofacial clefts: Association with maternal hyperhomocysteinemia. Teratology 1999; 60:253-57.
97. van Rooij IA, Swinkels DW, Blom HJ, Merkus HM, Steegers-Theunissen RP. Vitamin and homocysteine status of mothers and infants and the risk of nonsyndromic orofacial clefts. Am J Obstet Gynecol 2003; 189:1155-60.
98. Munger RG, Sauberlich HE, Corcoran C, Nepomuceno B, Daack-Hirsch S, Solon FS. Maternal vitamin B-6 and folate status and risk of oral cleft birth defects in the Philippines. Birth Defects Res A Clin Mol Teratol 2004; 70:464-71.
99. Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet A2003; 121A:95-101.
100. Tennstedt C, Chaoui R, Korner H, Dietel M. Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: Results of a seven year necropsy study. Heart 1999; 82:34-39.
101. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: Results from a population-based, case-control study. Pediatrics 1996; 98:911-17.
102. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol 1998; 78:151-61.
103. Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury MJ, Willett WC. Preconceptional folate intake and malformations of the cardiac outflow tract. Baltimore-Washington Infant Study Group. Epidemiology 1998; 9:95-98.
104. Botto LD, Lynberg MC, Erickson JD. Congenital heart defects, maternal febrile illness, and multivitamin use: A population-based study. Epidemiology 2001; 12: 485-90.
105. Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, Blom HJ, Eskes TK. Congenital heart defects and maternal derangement of homocysteine metabolism. J Pediatr 1999; 135:773-74.
106. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806-12.
107. Hobbs CA, Cleves MA, Melnyk S, Zhao W, James SJ. Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. Am J Clin Nutr 2005; 81:147-53.
108. Czeizel AE. The primary prevention of birth defects: Multivitamins or folic acid? Int J Med Sci 2004; 1:50-61.
109. Gordon TE, Leeth EA, Nowinski CJ, MacGregor SN, Kambich M, Silver RK. Geographic and temporal analysis of folate-sensitive fetal malformations. J Soc Gynecol Invest 2003; 10:298-301.
110. Yang Q, Khoury MJ, Olney RS, Mulinare J. Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring? Epidemiology 1997; 8:157-61.
111. Lin S, Marshall EG, Davidson GK, Roth GB, Druschel CM. Evaluation of congenital limb reduction defects in upstate New York. Teratology 1993; 47:127-35.
112. Wasserman CR, Shaw GM, O’Malley CD, Tolarova MM, Lammer EJ. Parental cigarette smoking and risk for congenital anomalies of the heart, neural tube, or limb. Teratology 1996; 53:261-67.
113. Botto LD, Mulinare J, Yang Q, Liu Y, Erickson JD. Autosomal trisomy and maternal use of multivitamin supplements. Am J Med Genet A 2004; 125A:113-16.
114. Czeizel AE, Puho E. Maternal use of nutritional supplements during the first month of pregnancy and decreased risk of Down’s syndrome: Case-control study. Nutrition2005; 21:698-704.
115. Zintzaras E. Maternal gene polymorphisms involved in folate metabolism and risk of Down syndrome offspring: A meta-analysis. J Hum Genet 2007; 52:943-53.
116. Botto LD, Mulinare J, Erickson JD. Occurrence of omphalocele in relation to maternal multivitamin use: A population-based study. Pediatrics 2002; 109:904-08.
117. Mills JL, Druschel CM, Pangilinan F, Pass K, Cox C, Seltzer RR, Conley MR, Brody LC. Folate-related genes and omphalocele. Am J Med Genet A 2005; 136:8-11.
118. Moore KL, Persaud TVN. The Developing Human: Clinically Oriented Embryology. 7th ed. Philadelphia: Saunders/Elsevier, 2003.
119. Shaw GM, Carmichael SL, Yang W, Harris JA, Lammer EJ. Congenital malformations in births with orofacial clefts among 3.6 million California births, 1983-1997. Am J Med Genet A 2004; 125A:250-56.
120. Myers MF, Li S, Correa-Villasenor A, Li Z, Moore CA, Hong SX, Berry RJ. Folic acid supplementation and risk for imperforate anus in China. Am J Epidemiol 2001; 154:1051-56.
121. Correa A, Botto L, Liu Y, Mulinare J, Erickson JD. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects? Pediatrics 2003; 111:1146-51.
122. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ 1993; 306:1645-48.
123. De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, et al.Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med2007; 357:135-42.